UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

Abstract

Background Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1 ( UGT1A1 ) is a predictive biomarker for the side-effects of irinotecan chemotherapy, which reduces the volume of tumors harboring UGT1A1 polymorphisms. We aimed to determine whether UGT1A1 polymorphisms can predict progression-free survival in patients with local cervical cancer treated with irinotecan chemotherapy. Methods We retrospectively analyzed the data of 51 patients with cervical cancer treated at a single institution between 2010 and 2015. All patients were diagnosed with 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IB1, IB2, IIA, or IIB squamous cell carcinoma, underwent radical hysterectomy, and received irinotecan chemotherapy as neoadjuvant and/or adjuvant treatment. All patients were examined for irinotecan side effects using UGT1A1 tests. Conditional inference tree and survival analyses were performed considering the FIGO stage, age, the UGT1A1 status, and the number of metastatic lymph nodes to determine primary factors associated with progression-free survival. Results The tree-structured survival model determined high recurrence-risk factors related to progression-free survival. The most relevant factor was ≥2 metastatic lymph nodes ( p = 0.004). The second most relevant factor was UGT1A1 genotype ( p = 0.024). Among patients with ≤1 metastatic lymph node, those with UGT1A1 polymorphisms benefited from irinotecan chemotherapy and demonstrated significantly longer progression-free survival ( p = 0.020) than those with wild-type UGT1A1 . Conclusions Irinotecan chemotherapy might be beneficial in patients with cervical cancer, UGT1A1 polymorphisms, and ≤ 1 metastatic lymph nodes.

Construction of Nursing Practice Model in Case Management of Concurrent Chemotherapy and Radiochemotherapy Treatment in Cervical Cancer

“…Cervical cancer is a malignant tumor that occurs in the cervix, vagina, and cervical canal. It is the most common reproductive tract cancer [12]. The incidence rate of malignant tumors is the second of gynecologic malignancies.…”

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen

“… 4 , 38 A recent study also found that neither UGT1A1*6 nor *28 had an impact on treatment efficacy and PFS in metastatic CRC; 34 however, Matsuoka et al suggested that UGT1A1 polymorphisms were significantly related with longer PFS in uterine cervical cancer. 39 Similarly, the findings by Henriksen et al revealed that UGT1A1*28 improved the PFS and OS in metastatic renal cell carcinoma. 40 In contrast, the study by Yamaguchi et al confirmed that UGT1A1*6 and *28 were shown to be related to a shorter OS in advanced gastric cancer when irinotecan monotherapy was used as a third-line treatment.…”

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis

“…Applying the exclusion criteria, 195 articles were removed and the remaining 105 full‐text articles were assessed in depth in line with the predetermined eligibility criteria. Finally, 42 articles were included in the meta‐analysis for assessing the associations of UGT1A1*6/UGT1A1*28 or ABCC2 c.3972C>T with irinotecan‐induced severe toxicities 12,14,21–24,26–31,34,35,48–75 . The complete selection process for the articles following PRISMA guidelines is shown in Figure 1.…”